| Biological Information | |
|---|---|
| Background Information: | Anti-B-cell maturation antigen (BCMA) antibodies are a class of drugs used to treat relapsed or refractory multiple myeloma (a type of cancer of the bone marrow) for adult patients who have received at least four other medications including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The only drug that belongs to this class is “belantamab mafodotin,” a humanized IgG1κ monoclonal antibody that targets the BCMA conjugated with a cytotoxic agent, maleimidocaproyl monomethylauristatin-F (MMAF). |
| Family: | TNFR Superfamily Receptor |
| Target Name: | BCMA |
| Usage | |
| Product Type: | Antibodies |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 4°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
Anti-BCMA Monoclonal Antibody
BCMA is a member of the TNF receptor superfamily and is expressed on B-cells. High BCMA expression is associated with cancer in plasma cells.
Datasheets
92-1356 Datasheet
View Document